Printer Friendly

ALPHA 1 BIOMEDICALS, INC. APPOINTS FRANK P. MAMARIL AS DIRECTOR OF QUALITY CONTROL

 BETHESDA, Md., June 17 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) announced today the appointment of Frank P. Mamaril, Ph.D. as Director of Quality Control. He will be responsible for supervising the company's Quality Control and Quality Assurance programs.
 Dr. Mamaril brings to the company a twenty-year career in quality control and quality assurance. This background covers compliance and regulatory experience with complex pharmaceutical biological products. Additionally, he spent eight years in related academic research. Most recently he served as Manager of Quality Control at Baxter Healthcare Corporation in Hayward, California. Previously he served in quality control management positions at Collagen Corporation in Palo Alto, California and Lederle/American Cyanamid in Pearl River, New York. Dr. Mamaril received a Ph.D. in Biochemistry from Kansas State University.
 Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 6/17/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, 301-564-4400 or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: PER

TM-MG -- NY098 -- 3326 06/17/93 17:52 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1993
Words:228
Previous Article:ENRON LIQUIDS PIPELINE, L.P. DECLARES SECOND QUARTER CASH DISTRIBUTION
Next Article:INFRASONICS ANTICIPATES LOWER YEAR-END EARNINGS BECAUSE OF FOURTH-QUARTER LOSS
Topics:


Related Articles
ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
/FOLLOWING IS A REPEAT OF A RELEASE MOVED YESTERDAY/
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
ALPHA 1 BIOMEDICALS APPOINTS MARTIN ROSE SENIOR VICE PRESIDENT, CLINICAL AND REGULATORY AFFAIRS
ALPHA 1 BIOMEDICALS NAMES ERNEST R. TYLER VICE PRESIDENT, OPERATIONS
ALPHA 1 BIOMEDICALS, INC. PROMOTES SUZANNE K. BECKNER TO VICE PRESIDENT, DEVELOPMENT
ALPHA 1 BI0MEDICALS, INC. APPOINTS MICHAEL L. BERMAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters